• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.

作者信息

Tomita Y, Sueta D, Kakiuchi Y, Saeki S, Saruwatari K, Sakata S, Jodai T, Migiyama Y, Akaike K, Hirosako S, Fujisue K, Yamamura S, Miyazaki S, Takashio S, Izumiya Y, Nakamura K, Tsujita K, Ichiyasu H, Fujii K

机构信息

Department of Respiratory Medicine.

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

出版信息

Ann Oncol. 2017 Nov 1;28(11):2893-2895. doi: 10.1093/annonc/mdx326.

DOI:10.1093/annonc/mdx326
PMID:28651328
Abstract
摘要

相似文献

1
Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.急性冠状动脉综合征作为一名对抗PD-1免疫检查点抗体获得完全缓解的肺癌患者可能出现的免疫相关不良事件。
Ann Oncol. 2017 Nov 1;28(11):2893-2895. doi: 10.1093/annonc/mdx326.
2
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.18F-氟代脱氧葡萄糖正电子发射断层扫描在评估复发非小细胞肺癌患者对纳武单抗的反应中的应用
World J Surg Oncol. 2016 Sep 5;14(1):238. doi: 10.1186/s12957-016-0998-y.
3
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.非小细胞肺癌患者接受纳武单抗治疗期间出现的与抗程序性死亡蛋白1相关的冷球蛋白血症。
Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.
4
Immune-related bone marrow failure following anti-PD1 therapy.抗PD1治疗后免疫相关的骨髓衰竭
Eur J Cancer. 2017 Jul;80:1-4. doi: 10.1016/j.ejca.2017.04.004. Epub 2017 May 17.
5
Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.口腔扁平苔藓样反应表现为与抗程序性死亡细胞受体-1 治疗相关的多个溃疡：两例报告和文献复习。
J Dermatol. 2018 May;45(5):587-591. doi: 10.1111/1346-8138.14205. Epub 2018 Jan 20.
6
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.化疗治疗与肺癌患者 PD-L1 表达的改变有关。
J Cancer Res Clin Oncol. 2018 Jul;144(7):1219-1226. doi: 10.1007/s00432-018-2642-4. Epub 2018 Apr 19.
7
Nivolumab-induced asthma in a patient with non-small-cell lung cancer.纳武单抗诱发非小细胞肺癌患者哮喘发作
Ann Oncol. 2017 Nov 1;28(11):2891. doi: 10.1093/annonc/mdx455.
8
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.大规模数字基因表达分析揭示了晚期肺癌腺癌和鳞状细胞癌中免疫检查点抑制剂治疗的不同预测特征。
BMC Cancer. 2022 Feb 8;22(1):154. doi: 10.1186/s12885-022-09264-2.
9
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合铂类双药化疗用于晚期非小细胞肺癌的一线治疗
J Clin Oncol. 2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861. Epub 2016 Jun 27.
10
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.晚期非小细胞肺癌患者中抗 PD-1 和抗 PD-L1 抗体免疫检查点抑制剂再挑战时的给药切换：病例系列和文献复习。
Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.

引用本文的文献

1
Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine-A Systematic Review.癌症免疫治疗中肠道微生物群的应用：机制、挑战及个性化医疗途径——一项系统综述
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251365700. doi: 10.1177/15330338251365700. Epub 2025 Aug 28.
2
Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes.癌症患者心肌缺血的机制：阻塞性与非阻塞性病因的最新综述
Rev Cardiovasc Med. 2022 Jun 24;23(7):227. doi: 10.31083/j.rcm2307227. eCollection 2022 Jul.
3
Immune checkpoint inhibitor-associated cardiovascular toxicities: A review.
免疫检查点抑制剂相关的心血管毒性：综述
Heliyon. 2024 Feb 9;10(5):e25747. doi: 10.1016/j.heliyon.2024.e25747. eCollection 2024 Mar 15.
4
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors.免疫检查点抑制剂引起的心脏毒性特征及相关因素的全面综述。
Eur J Med Res. 2023 Nov 8;28(1):495. doi: 10.1186/s40001-023-01464-1.
5
Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.可溶性 PD-L1 对冠心病患者心血管结局的预后意义。
J Atheroscler Thromb. 2024 Apr 1;31(4):355-367. doi: 10.5551/jat.64183. Epub 2023 Oct 3.
6
Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma.联合放疗与免疫检查点抑制治疗晚期肝细胞癌
Front Oncol. 2023 Jul 24;13:1193762. doi: 10.3389/fonc.2023.1193762. eCollection 2023.
7
Successful Management of Malignant Pericarditis Using Nivolumab for Metastatic Esophageal Squamous Cell Carcinoma.使用纳武单抗成功治疗转移性食管鳞状细胞癌所致恶性心包炎
Intern Med. 2024 Mar 1;63(5):677-680. doi: 10.2169/internalmedicine.2041-23. Epub 2023 Jul 19.
8
An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors.对动脉粥样硬化与免疫检查点抑制剂相关性的深入理解。
Curr Cardiol Rep. 2023 Aug;25(8):879-887. doi: 10.1007/s11886-023-01908-4. Epub 2023 Jul 3.
9
Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis.帕博利珠单抗与纳武利尤单抗在接受免疫检查点抑制剂治疗的癌症患者中的心脏毒性风险比较：一项荟萃分析。
Front Oncol. 2023 Mar 29;13:1080998. doi: 10.3389/fonc.2023.1080998. eCollection 2023.
10
Screening for Coronary Artery Disease in Cancer Survivors: State-of-the-Art Review.癌症幸存者冠状动脉疾病的筛查：最新综述
JACC CardioOncol. 2023 Feb 21;5(1):22-38. doi: 10.1016/j.jaccao.2022.12.007. eCollection 2023 Feb.